Shutterstock’s Partnership with Lightricks: A New Era of Data Licensing Empowering AI Through Collaboration In a groundbreaking move, Lightricks, a global leader in AI-powered creative technology, has announced a partnership with Shutterstock, Inc. This partnership marks the beginning of a new data licensing approach that aims to revolutionize the way AI models are trained. By…

Reclaiming Compliance: Spectral AI Regains Nasdaq Listing Rule 5550(b)(2) Requirements The Breakthrough Device Designation In December 2018, Spectral AI’s DeepView® System received the prestigious Breakthrough Device Designation from the U.S. FDA. This innovative system utilizes multi-spectral imaging and advanced algorithms to predict the potential for burn healing. Spectral AI has been at the forefront of…

The Schall Law Firm Reminds Investors of Class Action Lawsuit Against ASP Isotopes Inc. Overview: The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ASP Isotopes Inc. (“ASP Isotopes” or “the Company”) (NASDAQ:ASPI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934…

Aehr Test Systems, Inc. Investor Alert: Potential Recovery under Federal Securities Laws December 13, 2024 New York, NY / ACCESSWIRE If you suffered a loss on your Aehr Test Systems, Inc. (NASDAQ:AEHR) investment, you may be eligible for a potential recovery under the federal securities laws. Investors who have been affected by this matter are…

Crofelemer Trials and Scientific Showcase Webinar Crofelemer Clinical Efforts Crofelemer is the subject of five clinical efforts – three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies – for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa…

Exciting News in the Biopharmaceutical Industry! The Breakthrough Treatment for Transthyretin Amyloidosis It’s always heartwarming to hear about groundbreaking advancements in the medical field, and today is no exception. BridgeBio Pharma, Inc. has just announced a significant milestone in the treatment of transthyretin amyloidosis with the positive opinion recommending marketing authorization for acoramidis in the…

Bidding Farewell to the Securities: Kimco Realty Corporation Wraps Up Tender Offer A Not-So-Everyday Announcement So, picture this – just your average day in Jericho when a quirky piece of news breaks: Kimco Realty Corporation (NYSE: KIM) has decided to sweep up any and all of its outstanding depositary shares, referred to as Securities, representing…